NUK - logo
E-viri
Celotno besedilo
Recenzirano
  • Addition of AEG35156 XIAP A...
    Schimmer, Aaron D; Herr, Wolfgang; Hänel, Mathias; Borthakur, Gautham; Frankel, Arthur; Horst, Heinz-August; Martin, Sonja; Kassis, Jeannine; Desjardins, Pierre; Seiter, Karen; Fiedler, Walter; Noppeney, Richard; Giagounidis, Aristoteles; Jacob, Christine; Jolivet, Jacques; Tallman, Martin S; Koschmieder, Steffen

    Clinical lymphoma, myeloma and leukemia, 10/2011, Letnik: 11, Številka: 5
    Journal Article

    Abstract XIAP is over-expressed in AML and may contribute to chemoresistance. We report an open-label randomized phase II trial of reinduction chemotherapy with and without the XIAP antisense oligonucleotide AEG35156 in patients with AML patients. The addition of AEG35156 to re-induction chemotherapy did not improve rates of remission. Therefore, alternate therapeutic strategies should be explored in these patients.